株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症:世界の治験動向

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review, H1, 2015

発行 GlobalData 商品コード 226855
出版日 ページ情報 英文 92 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症:世界の治験動向 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review, H1, 2015
出版日: 2015年06月30日 ページ情報: 英文 92 Pages
概要

当レポートでは、メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症の治験 (臨床試験) に関する最新動向について分析しており、地域別の治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、各企業や研究機関における研究の進行状況、有望な薬剤の比較といった情報をまとめています。

イントロダクション

  • メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:感染症治療薬の治験におけるメチシリン耐性黄色ブドウ球菌 (MRSA) 感染症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:感染症治療薬の治験におけるメチシリン耐性黄色ブドウ球菌 (MRSA) 感染症の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

メチシリン耐性黄色ブドウ球菌 (MRSA) 感染症の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験のプロファイル

  • 主要企業の治験の概要
    • Pfizer Inc.
    • Khorakiwala Holdings and Investments Private Limited
    • AstraZeneca Plc
    • GlaxoSmithKline Plc
    • Forest Laboratories, Inc. (Inactive)
    • Cubist Pharmaceuticals, Inc. (Inactive)
    • Nabriva Therapeutics AG
    • MicuRx Pharmaceuticals, Inc.
    • Jaguar Holding Company II
    • Enanta Pharmaceuticals, Inc.
  • 代表的な研究機関・病院の治験の概要
    • University of California, Irvine
    • Washington University School of Medicine
    • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Assistance Publique - Hopitaux de Paris
    • Menzies School of Health Research
    • Seoul National University Bundang Hospital
    • Uniformed Services University of the Health Sciences
    • University Hospital, Geneva
    • University Medicine Greifswald
    • Wilford Hall Medical Center

5つの代表的な治験のプロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC2761CTIDB

GlobalData's clinical trial report, "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review, H1, 2015" provides an overview of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
      • Jun 02, 2015: Discovery of breakthrough MRSA compound
      • May 21, 2015: ContraFect Announces First Healthy Volunteer Dosed With CF-301
      • Apr 29, 2015: ContraFect Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA
      • Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance
      • Apr 24, 2015: New Data Shows Greater In Vitro Potency for VIBATIV (Telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, Compared to Alternative Antibiotic Treatments
      • Apr 16, 2015: Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV (telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, at 2015 ECCMID Conference
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Khorakiwala Holdings and Investments Private Limited
      • Clinical Trial Overview of Khorakiwala Holdings and Investments Private Limited
      • AstraZeneca Plc
      • Clinical Trial Overview of AstraZeneca Plc
      • GlaxoSmithKline Plc
      • Clinical Trial Overview of GlaxoSmithKline Plc
      • Forest Laboratories, Inc. (Inactive)
      • Clinical Trial Overview of Forest Laboratories, Inc. (Inactive)
      • Cubist Pharmaceuticals, Inc. (Inactive)
      • Clinical Trial Overview of Cubist Pharmaceuticals, Inc. (Inactive)
      • Nabriva Therapeutics AG
      • Clinical Trial Overview of Nabriva Therapeutics AG
      • MicuRx Pharmaceuticals, Inc.
      • Clinical Trial Overview of MicuRx Pharmaceuticals, Inc.
      • Jaguar Holding Company II
      • Clinical Trial Overview of Jaguar Holding Company II
      • Enanta Pharmaceuticals, Inc.
      • Clinical Trial Overview of Enanta Pharmaceuticals, Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • University of California, Irvine
      • Clinical Trial Overview of University of California, Irvine
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
      • Ann & Robert H. Lurie Children's Hospital of Chicago
      • Clinical Trial Overview of Ann & Robert H. Lurie Children's Hospital of Chicago
      • Assistance Publique - Hopitaux de Paris
      • Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
      • Menzies School of Health Research
      • Clinical Trial Overview of Menzies School of Health Research
      • Seoul National University Bundang Hospital
      • Clinical Trial Overview of Seoul National University Bundang Hospital
      • Uniformed Services University of the Health Sciences
      • Clinical Trial Overview of Uniformed Services University of the Health Sciences
      • University Hospital, Geneva
      • Clinical Trial Overview of University Hospital, Geneva
      • University Medicine Greifswald
      • Clinical Trial Overview of University Medicine Greifswald
      • Wilford Hall Medical Center
      • Clinical Trial Overview of Wilford Hall Medical Center
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015*
  • Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Suspended Clinical Trials, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Khorakiwala Holdings and Investments Private Limited, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline Plc, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Forest Laboratories, Inc. (Inactive), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc. (Inactive), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Nabriva Therapeutics AG, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by MicuRx Pharmaceuticals, Inc., 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Jaguar Holding Company II, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Enanta Pharmaceuticals, Inc., 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Ann & Robert H. Lurie Children's Hospital of Chicago, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Menzies School of Health Research, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Bundang Hospital, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Uniformed Services University of the Health Sciences, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Geneva, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medicine Greifswald, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Wilford Hall Medical Center, 2015*

List of Figures

  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015*
  • Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top